Vertex Pharmaceuticals and the art of starting over

The first thing to understand about Vertex Pharmaceuticals is that a successful drug can have a very short business life. Incivek, its hepatitis C medicine, arrived in 2011. By 2014, Vertex was abandoning the market. New treatments had changed what doctors could offer. A company that had finally learned to sell a blockbuster needed another future.

• The engine: medicines that address identifiable biological defects, led by cystic fibrosis.
• The expansion: gene-edited cells, non-opioid pain treatment and endocrine disease medicines.
• The catch: scientific success still has to survive competition, treatment logistics and reimbursement.

The blockbuster that became a warning

Incivek’s problem was brutally ordinary: something better came along. In the first half of 2014, sales fell to $13.2 million, down 96% from the same period a year earlier. Gilead’s Sovaldi helped redraw the market. Vertex discontinued U.S. sales that October. Approval had conferred permission to compete, with no promise about how long the opportunity would last.

The warning signs were visible earlier. In a regulatory response, Vertex described how encouraging competitor data at a 2012 liver-disease conference were followed by falling prescriptions for new Incivek patients. That is the useful detail. The scientific news changed expectations before the competing medicines had fully arrived. The company’s forecasts had to follow.

Vertex, founded in 1989 by Joshua Boger and Kevin J. Kinsella, already had another line of work. Its cystic fibrosis program offered a different competitive position: repair a malfunctioning protein involved in the disease itself. The retreat from hepatitis C made that work central to the company’s commercial future.

A foundation buys time

There is an unlikely financier in this story. In 2000, the Cystic Fibrosis Foundation committed $40 million to Aurora Biosciences to search for compounds that could correct defective CFTR protein function. Aurora used automated screening to test compounds in cells. Vertex acquired Aurora in 2001, inheriting a program backed by people with a very personal reason to keep it moving.

Kalydeco won FDA approval in 2012. Later combinations reached other eligible patients: Orkambi, Symdeko, Trikafta and Alyftrek. The point was to solve successive problems in how the protein was made and worked. A single disease could demand several medicines.

The Foundation’s return took an unusual form. In 2014, it sold royalty rights on Vertex CF treatments to Royalty Pharma for $3.3 billion. That money went to the nonprofit, which could finance more research and care. It was not Vertex buying the rights. Patient capital had helped create a commercial asset, then recycled the proceeds into the disease.

The expensive next experiment

Vertex’s business rests on prescription medicine sales, with CF supplying the established franchise. For chronic therapies, revenue repeats as patients continue treatment. Pharmacies, distributors, insurers and national health systems sit between the scientific result and the company’s income. That machinery helped produce approximately $12 billion in 2025 revenue.

Casgevy changes the operating problem. Developed with CRISPR Therapeutics, it became the first FDA-approved CRISPR-based treatment in December 2023, initially for eligible sickle cell patients. A patient’s blood stem cells are collected, edited to increase fetal hemoglobin and returned after conditioning chemotherapy. The product includes a demanding manufacturing and clinical journey.

Vertex paid CRISPR $900 million upfront under their 2021 revised agreement, taking 60% of program costs and profits. This was a partnership payment, not the total cost of inventing Casgevy. The distinction matters: drug-development economics include years of experiments, failed candidates, factories and obligations that a headline deal price cannot capture.

Journavx presents another test. Approved in January 2025 for moderate-to-severe acute pain in adults, it acts on NaV1.8 in the peripheral nervous system. Its trials showed better pain reduction than placebo. It enters a field crowded with familiar, often inexpensive medicines, where a new mechanism must earn a place in prescribing habits.

“We debate hard, listen hard and challenge each other with respect.”Vertex’s published culture and values

That stated culture suits a research business, provided the argument can end with a decision. Vertex disclosed that it stopped advancing VX-864 for alpha-1 antitrypsin deficiency in 2023 after non-serious rash events in some patients. A plausible target does not excuse an unacceptable drug profile. Stopping is part of the work.

Growth has a purchase price

The company also buys expertise. Vertex announced an approximately $4.9 billion cash agreement for Alpine Immune Sciences in 2024, adding povetacicept. In September 2026, it completed the Crinetics acquisition, announced at approximately $10 billion in equity value. That brought Palsonify for acromegaly and additional endocrine programs. Acquisition prices measure the transactions, not guaranteed returns.

The pipeline remains a set of questions. On September 22, 2026, Vertex reported Phase 2b inaxaplin results in APOL1-mediated kidney disease and completed enrollment in a later-stage trial. October brought interim Alyftrek data suggesting pancreatic-function recovery in some young children studied. Neither announcement warrants extending the findings beyond the patients and endpoints evaluated.

A medicine needs a way in

For patients, the practical route starts with a clinician establishing diagnosis, eligibility and an appropriate treatment. Vertex GPS helps eligible U.S. CF patients navigate support and insurance. Vertex Connects helps people prescribed gene therapy coordinate a more complicated process with authorized centers. These programs address the distance between having a medicine and receiving it.

The transferable lesson is to choose a problem precisely enough to test progress, then build the financing and delivery system around it. That approach needs a tractable biological target, meaningful clinical evidence and enough capital to tolerate disappointment. It struggles when the mechanism is unclear, treatment is impractical or reimbursement cannot support access. Vertex’s history offers both the incentive and the warning: the next answer can change a patient’s life, and it can also replace your business.